Skip to main content
. Author manuscript; available in PMC: 2012 Nov 1.
Published in final edited form as: Cancer Immunol Immunother. 2011 Jun 17;60(11):1543–1551. doi: 10.1007/s00262-011-1043-1

Table 1.

Cytokine profile of cells primed on OVA or APLs in the presence and absence of TGFβ

Priming peptide ± TGF/β1 Triple Double IL−2+, IFN-γ+ IL−2+, TNF-α+ IFN-γ+, TNF-α+ Single IL−2+ IFN-γ+ TNF-α+ No cytokines Cumulative
IL−2+ TFN-γ+ TNF-α+
OVA 33.98 29.29 27.02 2.27 0.00 26.58 26.34 0.18 0.06 10.24 89.61 36.31 61.18
+ 35.28 28.59 24.12 4.35 0.13 24.51 24.25 0.26 0.00 11.60 88.00 39.76 59.79
Y3 46.99 21.14 17.91 3.14 0.09 19.73 19.46 0.27 0.00 12.10 87.50 50.22 65.26
+ 36.38 17.63 12.92 4.47 0.24 22.01 21.83 0.12 0.06 24.05 75.60 41.15 49.66
Q4 51.03 14.45 11.97 2.48 0.00 20.74 20.52 0.18 0.05 13.76 86.00 53.56 63.18
+ 35.66 14.11 9.94 3.90 0.26 19.00 18.80 0.17 0.03 31.27 68.30 39.86 46.03
T4 59.10 10.52 6.17 4.07 0.28 12.45 12.03 0.28 0.14 17.86 81.37 63.59 65.83
+ 33.56 9.94 5.24 4.38 0.32 14.22 13.72 0.40 0.11 42.27 56.90 38.37 39.52
V4 67.47 7.26 3.93 2.62 0.71 5.95 5.55 0.20 0.20 19.31 79.58 71.01 72.32
24.67 8.19 2.54 5.22 0.44 17.69 17.58 0.07 0.04 49.45 50.01 30.37 27.72

OT-I splenocytes were primed and restimulated as shown in Fig. 1. The percentages of the resulting effector CD8+ T cells producing a particular set of cytokines or all of those producing an individual cytokine (Cumulative) are shown. Data shown are representative of at least three individual experiments with similar results